REG - Adv Medical Solutns. - Results of Annual General Meeting

Advanced Medical SolutionsAnnouncement

08/06/2022 14:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220608:nRSH1871Oa&default-theme=true

RNS Number : 1871O  Advanced Medical Solutions Grp PLC  08 June 2022

8 June 2022

 

Advanced Medical Solutions Group plc

("AMS" or the "Group")

 

Results of Annual General Meeting

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the
world-leading specialist in tissue-healing technologies, announces that at the
Company's Annual General Meeting held today at 11 am at the Offices of
Investec Bank plc, 30 Gresham Street, London, EC2V 7QP, all resolutions were
duly passed. Further details of each of the resolutions are set out in the
Notice of Meeting, which was sent to shareholders on 29 April 2022.

 

The poll results were as follows.

 

 Resolution  Title                                For (see note 2)        Against (see note 2)

             No. of shares                                     %          No. of shares  %
 1           Receive Annual Report and Accounts   122,189,273  99.99      2,000          0.01
 2           Approve the Remuneration Report      121,168,966  99.02      1,198,956      0.98
 3           Re-appoint Deloitte LLP as auditors  116,797,783  95.92      4,969,411      4.08
 4           Re-elect Peter Allen                 103,388,287  89.10      12,651,027     10.90
 5           Re-elect Grahame Cook                113,183,101  92.49      9,190,030      7.51
 6           Elect Douglas Le Fort                115,464,984  99.27      844,330        0.73
 7           Re-elect Chris Meredith              120,304,522  98.31      2,068,609      1.69
 8           Re-elect Eddie Johnson               122,028,446  99.72      344,685        0.28
 9           Declare final dividend               122,378,935  99.99      1,121          0.01
 10          Authorise allotment of shares        117,948,199  96.38      4,430,807      3.62
 11          Disapply pre-emption rights*         108,025,798  88.28      14,345,022     11.72
 12          Authorise purchase of own shares*    94,316,659   99.05      907,369        0.95

*  Special Resolution

 Notes:

 1.  Votes "For" and "Against" are expressed as a percentage of votes
 received.

 2.  A "Vote withheld" is not a vote in law and is not counted in the
 calculation of the votes "For" or "Against" a resolution.

 3.  Total number of shares in issue at close of business on 6 June =
 216,626,583 shares. 56% of the voting capital was instructed.

 

- Ends -

 

 

For further information, please visit www.admedsol.com
(http://www.admedsol.com) or contact:

 

 Advanced Medical Solutions Group plc             Tel: +44 (0) 1606 545508
 Chris Meredith, Chief Executive Officer

 Eddie Johnson, Chief Financial Officer

 Consilium Strategic Communications               Tel: +44 (0) 20 3709 5700
 Mary-Jane Elliott / Matthew Neal / Matthew Cole  AMS@consilium-comms.com

 Investec Bank PLC (NOMAD & Broker)               Tel: +44 (0) 20 7597 5970
 Daniel Adams / Gary Clarence

 HSBC Bank PLC (Broker)                           Tel: 44 (0) 20 7991 8888
 Sam McLennan / Joe Weaving / Stephanie Cornish

 

About Advanced Medical Solutions Group plc - see www.admedsol.com
(http://www.admedsol.com)

AMS is a world-leading independent developer and manufacturer of innovative
tissue-healing technology, focused on quality outcomes for patients and value
for payers. AMS has a wide range of surgical products including tissue
adhesives, sutures, haemostats, internal fixation devices and internal
sealants, which it markets under its brands LiquiBand(®), RESORBA(®),
LiquiBandFix8(®) and Seal-G(®). AMS also supplies wound care dressings such
as silver alginates, alginates and foams through its ActivHeal(®) brand as
well as under white label. Since 2019, the Group has made four acquisitions:
Sealantis, an Israeli medical device company with a patent-protected sealant
technology platform; Biomatlante, an established French developer and
manufacturer of innovative surgical biomaterial technologies, Raleigh, a UK
leading coater and converter of materials predominately for woundcare and
bio-diagnostics products and AFS Medical, a specialist distributor of
minimally invasive surgical devices based in Austria.

 

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the
Czech Republic and Israel, are sold globally via a network of multinational or
regional partners and distributors, as well as via AMS's own direct sales
forces in the UK, Germany, the Czech Republic and Russia. The Group has
R&D innovation hubs in the UK, Germany, France and Israel. Established in
1991, the Group has more than 700 employees. For more information, please see
www.admedsol.com (http://www.admedsol.com) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGFLFSFRDITIIF